North West Coast
Strategic Clinical Networks

Weekly bortezomib (subcutaneous), cyclophosphamide and dexamethasone

INDICATION: Myeloma

Prior to a course of treatment

- Check creatinine clearance – *see dose modification*.
- Assess cardiac function by history and exam with ECG, CXR. Consider MUGA scan if abnormal. Note bortezomib is contraindicated if severe cardiac impairment.
- Assess for peripheral neuropathy –may worsen on therapy; contraindicated if ≥ Grade 3 sensory
- Check FBC – neutrophils must be > 0.5, platelets >25 unless due to marrow infiltration
- Check LFTs – *see dose modification.*
- If appropriate discuss possibility of pregnancy with female patients and need for contraception with both male and female patients. Discuss potential for infertility - offer semen cryopreservation to male patients
- Written consent for course
- With severe renal failure consideration should be given to using other bortezomib combinations. Consultant medical decision.

Prior to each cycle

- Medical review of fitness for chemotherapy – exclude active infection, major changes in organ function.
- Check FBC, U&Es, creat, LFTs – *see dose modification*. *Discuss with consultant* if renal or hepatic function have changed change significantly.
- Encourage patient to drink 3 L fluid daily

Prior to each dose

- Reassess for peripheral neuropathy – *see dose modifications*
- Check FBC - give blood product and GCSF support as necessary during the cycle

Bortezomib	1.3mg/m^2	subcutaneous injection	Days 1, 8, 15, 22
Dexamethasone	20mg od	PO	Days 1,2 8,9 15,16 22,23
Cyclophosphamide	500mg	PO	Days 1, 8, 15, 22

Repeat cycle every 35 days

- Plan to give at least 2 cycles to assess response
- If CR is achieved give an additional 2 cycles up to a maximum of 8 cycles
- If there is partial or marginal response give an additional 2 cycles after plateau up to max. 8 cycles
- Consider alternative of dexamethasone 40mg od for 4 days every 2 weeks to first cycle

Anti-emetic prophylaxis	Metoclopramide
Other medications	Allopurinol 300mg od (100mg if Cr.Cl <20ml/min) for cycle 1 Aciclovir 400mg bd prophylactically

Dose modification for haematological toxicity (unless due to disease)

• Neutrophils <0.5 or platelets <25 on day 1 of cycle	Withhold until recovery then restart with 25% dose reduction
• No resolution of cytopaenia or they recur at 0.7mg/m^2	If no resolution or recurs at lowest dose, consider stopping treatment – *discuss with consultant*

Dose modifications of bortezomib for peripheral neuropathy

• Grade 1 (but no pain) i.e loss of tendon reflexes or paraesthesiae but not interfering with function	No change
• Grade 1 with pain or Grade 2, i.e objective sensory loss or paraesthesia interfering with function but not activities of daily living	Reduce to 1.0mg/m^2
• Grade 2 with pain or Grade 3, i.e sensory loss or paraesthesia interfering with activities of daily living	Withhold until symptoms resolve, then restart at 0.7mg/m^2 at <u>once</u> a week
• Grade 4, i.e permanent sensory loss that interferes with function	Discontinue bortezomib

Modification for renal dysfunction

- If < 30ml/min *discuss with consultant*. Note that the incidence of serious adverse effects increases with mild-moderate renal impairment. Patients have been treated safely when the creatinine clearance is<30ml/min and on dialysis but monitor carefully for toxicities if renal function is impaired
- If <30ml/min consider alternative less renal toxic regime. Consultant clinical decision.

Modification for liver dysfunction

- The major route of bortezomib excretion is hepatic and there is limited on the use of bortezomib in patients with hepatic impairment. If bilirubin >30μmol/L use with caution, monitor closely for toxicity and consider dose reduction – *discuss with consultant*

Dose modification for diarrhoea	
• If ≥ grade 3 diarrhoea, i.e increase of ≥ 7 stools/day over baseline, incontinence, hospitalization with >24 hrs IV fluids	Reduce dose to 1.0mg/m^2, then 0.7mg/m^2 if symptoms persist

Bortezomib Toxicities	
Thrombocytopenia	Nausea
Neutropenic sepsis	Fatigue
Fluid retention & cardiac failure	Diarrhoea, constipation & ileus
Peripheral neuropathy (may be painful)	Hypotension
Fatigue, malaise, weakness	Injection site reaction

Written by	Dr Giamal Sager Consultant Haematologist
Date	August 2016
Review date	August 2018